The major serum binding protein of salmon calcitonin (sCT) in the rat was identified. High-molecular-weight (HMW) forms of sCT, produced by the incubation of radioactive sCT in rat serum, were isolated by gel filtration and analysed by chromatofocusing. The major radioactive peak was eluted at the region of albumin in gel filtration, and this peak had a slightly higher pI than albumin on chromatofocusing. Immunoreactivity of the radioactive peak fraction in chromatofocusing, examined by immunodiffusion, showed that the major protein in the fraction was albumin. Immunoreactivity of the radioactive HMW fraction isolated by gel filtration was studied by immunoprecipitation, indicating that a large portion of the fraction reacted with anti-rat albumin antiserum. These results suggested that the radioactive peak in chromatofocusing represents the complex of sCT and rat albumin. Further, HMW forms of sCT were analysed by immunoelectrophoresis and autoradiography, and most of the radioactivity was found on the precipitation line of albumin. These results demonstrate that the major binding protein of sCT in rat serum is albumin.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0006-2952(85)90731-2 | DOI Listing |
BMC Musculoskelet Disord
December 2024
Guangzhou University of Chinese Medicine, Guangzhou, China.
Background: Low back pain is a major disorder that causes disability and is strongly associated with intervertebral disc degeneration (IDD). Because of the limitations of contemporary interventions, stem cell transplantation (SCT) has been increasingly used to regenerate degenerative discs. Nevertheless, analyses of high-impact papers in this field are rare.
View Article and Find Full Text PDFActa Neuropsychiatr
December 2024
Department of Pharmacology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Objective: Combining different pharmaceuticals may be beneficial when treating disorders with complex neurobiology, including alcohol use disorder (AUD). The gut-brain peptides amylin and GLP-1 may be of potential interest as they individually reduce alcohol intake in rodents. While the combination of amylin receptor (AMYR) and glucagon-like peptide-1 receptor (GLP-1R) agonists have been found to decrease feeding and body weight in obese male rats synergistically, their combined impact on alcohol intake is unknown.
View Article and Find Full Text PDFBr J Pharmacol
December 2024
Institute of Neuroscience and Physiology, Department of Pharmacology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Background And Purpose: The limited effectiveness of current pharmacological treatments for alcohol use disorder (AUD) highlights the need for novel therapies. These may involve the glucagon-like peptide-1 receptor or the amylin receptor, as treatment with agonists targeting either of these receptors lowers alcohol intake. The complexity of the mechanisms underlying AUD indicates that combining agents could enhance treatment efficacy.
View Article and Find Full Text PDFNeuroscience
October 2024
Department of Biomedicine, Experimental Biology Unit, Faculty of Medicine of Porto, University of Porto, Portugal; Pain Neurobiology, Instituto de Investigação e Inovação em Saúde-i3S and IBMC, Universidade do Porto, Porto, Portugal. Electronic address:
Int Braz J Urol
September 2024
Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Objective: To describe the evidence of Platelet Rich Plasma (PRP), Stem cells therapy (SCT) and Extracorporeal shockwave therapy (ESWL) for the treatment of Peyronies disease (PD), including information from the main urological society guidelines.
Materials And Methods: A literature review of PubMed articles published between 2000 and 2023 was conducted, utilizing keywords such as "Peyronie's Disease", "Penile curvature", "Platelet Rich Plasma", "Stem cells", and "Extracorporeal shockwave therapy". Only full-text articles in English were included, excluding case reports and opinions.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!